Nearly 12 million intravitreal injections for ophthalmic disease were admistered to patients eyes in 2012, and the figure is a testament to the acceptability of the delivery method whose very concept once inspired gasps and doubts; still, meaningful improvements are almost certain to be welcome and reimbursed in the marketplace. GrayBug LLC is betting it can enhance the outcome of drugs injected into the eye by prolonging their release with a polymer-based delivery system that the firm expects to eventually be formulated as nanoparticles – the goal is to extend intervals between ocular medicine dosing to three months or longer, perhaps as long as six months, with reduced inflammatory effects.
400 North Broadway
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?
Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.
Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.
